成都圣诺生物科技股份有限公司 关于自愿披露维培那肽原料药获得上市申请批准通知书的公告

Group 1 - The core point of the article is the approval of the上市申请 for Visepegenatide, a chemical raw material drug, by the National Medical Products Administration, which reflects the company's comprehensive strength in R&D, production, and quality management [1][3] Group 2 - Visepegenatide is a PEGylated form of Exenatide that acts as a GLP-1 receptor agonist, mimicking the physiological effects of natural GLP-1, enhancing insulin secretion, and lowering blood glucose levels in a glucose-dependent manner, thus treating type 2 diabetes and obesity [2] Group 3 - The approval of Visepegenatide's上市申请 is expected to positively impact the company's operational development and accumulate valuable experience for future drug research [3]